Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis | The Manila Times

Anmeldung erfolgt in Kürze...

query
ai

Details werden geladen...

https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-for-the-management-of-symptomatic-knee-osteoarthritis/2379344

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis | The Manila Times

PDUFA Target Action Date Set for April 24, 2027

Ähnliche Seiten

https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/alvotech-announces-fda-acceptance-of-biologics-license-application-for-avt16-a-proposed-interchangeable-biosimilar-to-entyvio/2360479

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® | The Manila Times

https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/alvotech-announces-fda-acceptance-of-biologics-license-application-for-avt16-a-proposed-interchangeable-biosimilar-to-entyvio/2360479

https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/zenas-biopharma-announces-submission-of-biologics-license-application-bla-to-us-fda-for-obexelimab-in-igg4-rd/2353517

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | The Manila Times

https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/zenas-biopharma-announces-submission-of-biologics-license-application-bla-to-us-fda-for-obexelimab-in-igg4-rd/2353517

https://www.manilatimes.net/2026/06/26/tmt-newswire/pr-newswire/everest-medicines-announces-china-nmpa-acceptance-of-the-biologics-license-application-for-lerochol-in-adults-with-hypercholesterolemia/2373425

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia | The Manila Times

https://www.manilatimes.net/2026/06/26/tmt-newswire/pr-newswire/everest-medicines-announces-china-nmpa-acceptance-of-the-biologics-license-application-for-lerochol-in-adults-with-hypercholesterolemia/2373425

https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/alvotech-announces-resubmission-of-us-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-and-avt06-a-proposed-biosimilar-to-eylea/2358521

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® | The Manila Times

https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/alvotech-announces-resubmission-of-us-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-and-avt06-a-proposed-biosimilar-to-eylea/2358521

https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/allarity-therapeutics-announces-clia-certification-clearing-the-path-for-advancing-drp-testing-for-fda-registration/2379856

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration | The Manila Times

https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/allarity-therapeutics-announces-clia-certification-clearing-the-path-for-advancing-drp-testing-for-fda-registration/2379856

https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/analyzing-the-progress-of-malaysia-rmo-dax-license-application-for-skhtu-exchange/2365309

Analyzing the Progress of Malaysia RMO (DAX) License Application for SKHTU Exchange | The Manila Times

https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/analyzing-the-progress-of-malaysia-rmo-dax-license-application-for-skhtu-exchange/2365309